Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
Adds a new Medicare Part B benefit covering certain pharmacist services, defines eligible pharmacist services (including visits for evaluation/management and testing/treatment for respiratory infections and declared public-health-emergency needs), requires services follow applicable State supervision/collaboration rules, sets a payment formula (Medicare payment equal to 80% of the lesser of actual charge or 85% of the applicable physician/payment-basis amount, with 100% used for public-health-need services), prohibits balance billing by pharmacists, and makes the changes effective January 1, 2026.
Liberals emphasize access and public-health benefits; conservatives stress federal cost and expansion.
Relative to its intended legislative type, this bill is a direct statutory amendment that establishes Medicare Part B coverage and payment parameters for certain pharmacist-provided testing and treatment services, integrates into existing Medicare statutory sections, and specifies an effective date.
Adds a new Medicare Part B benefit covering certain pharmacist services, defines eligible pharmacist services (including visits for evaluation/management and testing/treatment for respiratory infections and declared public-health-emergency needs), requires services follow applicable State supervision/collaboration rules, sets a payment formula (Medicare payment equal to 80% of the lesser of actual charge or 85% of the applicable physician/payment-basis amount, with 100% used for public-health-need services), prohibits balance billing by pharmacists, and makes the changes effective January 1, 2026.
Practically narrow and administrable, with likely stakeholder debate on scope and costs; passing both chambers requires negotiating payment and professional-group concerns.
Relative to its intended legislative type, this bill is a direct statutory amendment that establishes Medicare Part B coverage and payment parameters for certain pharmacist-provided testing and treatment services, integrates into existing Medicare statutory sections, and specifies an effective date.
Liberals emphasize access and public-health benefits; conservatives stress federal cost and expansion.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize access and public-health benefits; conservatives stress federal cost and expansion.
Generally supportive: expands access to community-based care, strengthens epidemic response, and protects patients from surprise billing.
Sees pharmacists as an underutilized workforce for testing and treatment.
Some concerns about limited scope and payment adequacy.
Cautiously favorable as a pragmatic, incremental expansion of Medicare provider types that leverages existing pharmacy capacity.
Appreciates defined payment mechanism and balance-billing prohibition, but wants clarity on costs, oversight, and operational details.
Skeptical: cautious about expanding federal coverage and adding a new Medicare-paid provider category.
May appreciate increased access but worries about federal costs, regulatory expansion, and impacts on physician-led care.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Practically narrow and administrable, with likely stakeholder debate on scope and costs; passing both chambers requires negotiating payment and professional-group concerns.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize access and public-health benefits; conservatives stress federal cost and expansion.
Practically narrow and administrable, with likely stakeholder debate on scope and costs; passing both chambers requires negotiating payment…
Relative to its intended legislative type, this bill is a direct statutory amendment that establishes Medicare Part B coverage and payment parameters for certain pharmacist-provided testing and treatment services, integ…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.